Director, @ncats_nih_gov. #WomanInScience and Kansan. Advocate for science and improving health for all. Drone, đź”, and nature hobbyist. Views are mine.
The #AssayGuidanceManual Webinar featuring Nobel laureate Dr. Carolyn Bertozzi is tomorrow! Don’t forget to register and tune in at 11 a.m. EDT to hear more on New Therapeutic Modalities Inspired by Glycoscience: sites.google.com/ncats.nih.g…#Glycoscience
ALT 2025 AGM Preclinical Translational Science Webinar Series. New Therapeutic Modalities Inspired by Glycoscience. Carolyn Bertozzi, Ph.D. Baker Family Director of Sarafan Stanford ChEM-H and the Anne T. and Robert M. Bass Professor of Humanities and Sciences in the Department of Chemistry, Stanford University. Thursday, June 12, 2025, from 11 a.m. to 12 p.m. EDT. NIH NCATS logo. The Assay Guidance Manual.
Friendly reminder that if you have thoughts about the current state of postdoctoral research training and career progression within the biomedical research enterprise, the @NIH would like to hear from you by April 14, 2023 📝💻bit.ly/3lDU2s0
P.J. Brooks, Ph.D., Acting Director of the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS)@ncats_nih_gov, describes the two main types of gene therapy currently in development. @rarediseasesnetcheckrare.com/ex-vivo-vs-in-…
#Clinicaltrials research the way a drug or treatment will interact with the human body, and are critical for determining safety and efficacy. Learn about what it's like to participate in a #genetherapy clinical trial ⬇️
Want to learn more about what it’s like to participate in a #GeneTherapy clinical trial? Join FDA’s public workshop on April 13 to hear inspiring stories from patients, caregivers, and advocates who have navigated #ClinicalTrials. Register ➡️ bit.ly/3l01XQA#RegenMedEd
ALT Clinical Trials: The Patient Experience. Hear inspiring stories from patients with rare diseases, caregivers, and advocates who have navigated gene therapy clinical trials. April 13, 2023. 11:00 am – 3:00 pm. #regenmeded
#CTSAProgram researchers redrew United States maps of three #FungalInfections and found they have spread outside their usual regions of infection, causing severe and life-threatening infections. Learn more about the study findings: bit.ly/3xILxPq
ALT Illustration shows the fungus that causes coccidioidomycosis, also known as Valley fever.
Collaboration is at the heart of what we do at NCATS! Hear from NCATS’ Matt Hall, Ph.D., about what could be next for #DrugRepurposing or #DrugDevelopment in collaboration with the Bardeesy Lab at @MassGeneralNews. 👀
Scientists at @NIH & @MassGeneralNews uncovered a potential new approach against #LiverCancer that could lead to the development of new anticancer drugs. 1/2
Catch up with CRISPR TODAY at 12pm (ET)❗️
#SCGE PI @ESontheimerLab joins CRISPR pioneers for a free webinar highlighting the current opportunities and challenges for #CRISPR technology.
Register ⬇️
On March 16 at 12 p.m. ET, join world-renowned #CRISPR pioneers @CRISPRchef, @ESontheimerLab, & @MarraffiniLab for a free webinar related to their ASM and @wileymicrobio book, “CRISPR: Biology and Applications.” Reserve your seat now: asm.social/14W
ALT Register now for the free ASM-Wiley webinar, "Catching up with CRISPR."
Join our team! We're hiring a director for NCATS’ Office of Strategic Alliances. The candidate will manage the technology transfer program & serve as an advisor to NCATS leadership on matters related to NCATS’ #SBIR and #STTR programs, patenting & more.
bit.ly/3leKO5I
ALT We are hiring for a new Director of the Office of Strategic Alliances. National Institutes of Health, National Center for Advancing Translational Sciences logo.
“It’s not rocket science, but to do the science we need the rockets.” – NCATS Director Joni Rutter
The tiny technology held by Dr. Rutter is an example of the #TissueChips that will head to the @Space_Station to speed research on health and the development of new treatments.
ALT Photo of three people with one holding a tissue chip.
"It's not rocket science, but we do need rockets to do the science," @jonirutter on @ncats_nih_gov collaboration with @NASA to discover new insights into the aging process.
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s AtaxiaÂ
Click here to read the full press release:  reatapharma.com/investors/ne…
Speakers in #RDDNIH session 1 highlighted the importance of finding and connecting existing data to help the #RareDiseases community understand rare diseases and advance research. #RareDiseaseDay
ALT Photo of the Rare Disease Alert System on a slide at Rare Disease Day at NIH 2023.
“Diversity in #genomics is not just good for the African population. It’s good for all of us… It’s even more important to think about the growing diversity of our country.” — Tshaka J. Cunningham, Ph.D. #RDDNIH#RareDiseaseDay
ALT Tshaka J. Cunningham, Ph.D., presents during Rare Disease Day at NIH 2023.
Congress, here we come!
These rare disease advocates are coming your way to make their voices heard.
Shout out to our virtual advocates and everyone who couldn't make it in person. 🦓🙌
#RareDC2023#legislativeconference#washingtondc#capitolhill
Happening now at #RDDNIH ➡️ Session 4: #RareDiseases Therapeutics and the Role of Advocacy and Industry Collaborations
âś… Featuring Kristen Wheeden, MBA, Rare Disease Caregiver; CPAG Representative, #Porphyrias Consortium (PC)
Join the livestream: videocast.nih.gov/livew.asp?…
“It’s time to move away from only natural history clinical trials as we work toward first-in-human studies.” - James K. Gilman, MD
#RareDiseaseDay#RDDNIH#RareDiseaseDay2023
ALT Quoted from NIH Rare Disease Day 2023 in person event: “It’s time to move away from only natural history clinical trials as we work toward first-in-human studies.” - James K. Gilman, MD
#RareDiseaseDay #RDDNIH #RareDiseaseDay2023